慢淋治疗加速迈进“无化疗时代”

Core Insights - The successful launch of the "Acalabrutinib 1L CLL/SLL Indication Medical Insurance Implementation Press Conference" during the CSCO meeting highlights the clinical significance of Acalabrutinib's inclusion in medical insurance for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1][2] - Acalabrutinib has previously been included in medical insurance for three lymphoma-related indications, covering various clinical scenarios in lymphoma treatment [1] - The median age of CLL patients in China is 65, with an increasing incidence due to an aging population and improved diagnostic capabilities, posing a significant health threat to the elderly [1] Group 1 - The rise of targeted therapies has transformed the treatment model for CLL, with Acalabrutinib leading the shift towards a "chemotherapy-free era" [2] - Phase III studies show that after 12 months of treatment with Acalabrutinib, the progression-free survival (PFS) rate is 93.1%, and after 18 months, the overall survival (OS) rate is 96.7% [2] - The inclusion of Acalabrutinib in medical insurance as of January 1, 2026, represents a critical transition from "available" to "accessible" for a broader patient population [2] Group 2 - The implementation of Acalabrutinib in medical insurance significantly reduces the economic burden on patients and accelerates the transition from chemotherapy to a chemotherapy-free treatment model [2] - Ongoing exploration of Acalabrutinib combination therapies aims to achieve deeper remission and promote individualized, precise treatment approaches [2] - Evidence from registration studies indicates that Acalabrutinib monotherapy for relapsed/refractory CLL patients shows a complete response (CR) rate of 26.3% after a median follow-up of 33.1 months, with a discontinuation rate of only 7.5% and no incidence of grade 3 or higher atrial fibrillation [2]